[go: up one dir, main page]

MA29481B1 - Derives d'azolopyridine-2-one en tant qu'inhibiteurs de lipase et de phospholipase - Google Patents

Derives d'azolopyridine-2-one en tant qu'inhibiteurs de lipase et de phospholipase

Info

Publication number
MA29481B1
MA29481B1 MA30415A MA30415A MA29481B1 MA 29481 B1 MA29481 B1 MA 29481B1 MA 30415 A MA30415 A MA 30415A MA 30415 A MA30415 A MA 30415A MA 29481 B1 MA29481 B1 MA 29481B1
Authority
MA
Morocco
Prior art keywords
derivatives
azolopyridine
lipase
phospholipase inhibitors
salts
Prior art date
Application number
MA30415A
Other languages
English (en)
Inventor
Gerhard Zoller
Stefan Petry
Guenter Mueller
Hubert Heuer
Norbert Tennagels
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA29481B1 publication Critical patent/MA29481B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/424Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

DÉRIVÉS D'AZOLOPYRIDIN-2-ONE DE FORMULE GÉNÉRALE (I) AYANT LES SIGNIFICATIONS FIGURANT DANS LA DESCRIPTION, SELS DESDITS DÉRIVÉS POUVANT ÊTRE UTILISÉS SUR LE PLAN PHARMACEUTIQUE ET UTILISATION DESDITS DÉRIVÉS ET SELS EN TANT QUE SUBSTANCES MÉDICAMENTEUSES.
MA30415A 2005-06-09 2007-11-22 Derives d'azolopyridine-2-one en tant qu'inhibiteurs de lipase et de phospholipase MA29481B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005026762A DE102005026762A1 (de) 2005-06-09 2005-06-09 Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen

Publications (1)

Publication Number Publication Date
MA29481B1 true MA29481B1 (fr) 2008-05-02

Family

ID=37076291

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30415A MA29481B1 (fr) 2005-06-09 2007-11-22 Derives d'azolopyridine-2-one en tant qu'inhibiteurs de lipase et de phospholipase

Country Status (30)

Country Link
US (2) US7846943B2 (fr)
EP (1) EP1896485B1 (fr)
JP (1) JP2008542410A (fr)
KR (1) KR20080019215A (fr)
CN (1) CN101193896A (fr)
AR (1) AR054132A1 (fr)
AT (1) ATE468342T1 (fr)
AU (1) AU2006257022A1 (fr)
BR (1) BRPI0611688A2 (fr)
CA (1) CA2610325A1 (fr)
CY (1) CY1110213T1 (fr)
DE (2) DE102005026762A1 (fr)
DK (1) DK1896485T3 (fr)
ES (1) ES2346561T3 (fr)
HR (1) HRP20100409T1 (fr)
IL (1) IL187730A0 (fr)
MA (1) MA29481B1 (fr)
MX (1) MX2007015347A (fr)
MY (1) MY142792A (fr)
NO (1) NO20080133L (fr)
NZ (1) NZ564063A (fr)
PL (1) PL1896485T3 (fr)
PT (1) PT1896485E (fr)
RS (1) RS51268B (fr)
RU (1) RU2414473C2 (fr)
SI (1) SI1896485T1 (fr)
TW (1) TW200716653A (fr)
UY (1) UY29593A1 (fr)
WO (1) WO2006131231A1 (fr)
ZA (1) ZA200709501B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006014685A1 (de) 2006-03-28 2007-10-04 Sanofi-Aventis Imidazo-pyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholiphasen
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
EP2351744B1 (fr) 2008-10-17 2015-01-07 Shionogi & Co., Ltd. Dérivé amide d'acide acétique ayant une activité inhibitrice d'une lipase endothéliale vasculaire
CA2779303A1 (fr) * 2009-10-29 2011-05-19 Sirtris Pharmaceuticals, Inc. Pyridines bicycliques et analogues en tant que modulateurs de la sirtuine
KR20120123325A (ko) 2009-12-15 2012-11-08 시오노기세야쿠 가부시키가이샤 혈관 내피 리파아제 저해 활성을 갖는 옥사디아졸 유도체
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
CN114560873B (zh) * 2021-12-27 2023-02-28 浙江日出药业有限公司 一种3-氯甲基-6-氯-噁唑[4,5-b]吡啶-2(3H)酮的制备方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3835576A1 (de) * 1988-03-25 1989-10-12 Bayer Ag 3,7-disubstituierte benzthiazolone
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663634B1 (fr) * 1990-06-22 1992-09-04 Adir Nouvelles acyl benzoxazolinones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
CA2241567A1 (fr) 1996-01-17 1997-07-24 Novo Nordisk A/S Derives de 1,2,4-thiadiazine fusionnee et de 1,4-thiazine fusionnee, leur preparation et utilisation
UA72181C2 (uk) 1996-08-30 2005-02-15 Ново Нордіск А/С Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
RU2200161C2 (ru) 1996-12-31 2003-03-10 Др. Редди'З Рисерч Фаундейшн Новые производные азолидиндиона, способ их получения (варианты), фармацевтические композиции на их основе, способ предупреждения или лечения, способ снижения глюкозы и промежуточное соединение
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
IL133604A0 (en) 1997-07-16 2001-04-30 Novo Nordisk As Fused 1, 2, 4-thiadiazine derivatives, their preparation and use
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
WO2000063208A1 (fr) 1999-04-16 2000-10-26 Novo Nordisk A/S Imidazoles substitues, leur preparation et utilisation
DE60027420T2 (de) 1999-04-28 2006-11-16 Aventis Pharma Deutschland Gmbh Tri-aryl-säurederivate als ppar rezeptor liganden
DK1177187T3 (da) 1999-04-28 2007-10-15 Sanofi Aventis Deutschland Diarylsyrederivater som PPAR-receptorligander
AU4808300A (en) 1999-04-30 2000-11-17 Neurogen Corporation 9h-pyrimido(4,5-b)indole derivatives: crf1 specific ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
AU773505B2 (en) 1999-06-18 2004-05-27 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
JP2003504082A (ja) 1999-07-09 2003-02-04 コヘージョン テクノロジーズ, インコーポレイテッド エカリンポリペプチド、エカリンをコードするポリヌクレオチド、及びその利用のための方法
ATE245636T1 (de) 1999-07-29 2003-08-15 Lilly Co Eli Benzofurylpiperazine: 5-ht2c serotoninrezeptor agonisten
KR20020033778A (ko) 1999-09-01 2002-05-07 로버트 흐라이탁, 미쉘 베스트 설포닐 카복스아미드 유도체, 이의 제조방법 및약제로서의 이의 용도
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
PT1237855E (pt) 1999-12-03 2004-06-30 Astrazeneca Ab Forma cristalina do acido (s)-2-etoxi-3-¬4-(2-{4-metanosulfoniloxifenil}etoxi)fenil|propanoico
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
FR2804431A1 (fr) * 2000-02-02 2001-08-03 Adir Nouveaux derives heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2400226C (fr) 2000-03-31 2007-01-02 Probiodrug Ag Procede destine a ameliorer le signalement d'ilots dans le diabete sucre et a prevenir ce dernier
YU80302A (sh) 2000-04-25 2005-11-28 Kyorin Pharmaceutical Co. Ltd. Novi stabilni kristal derivata tiazolidinediona i postupak za proizvodnju istog
PT1277736E (pt) 2000-04-28 2007-10-12 Asahi Kasei Pharma Corp Novos compostos bicíclicos
ES2252230T3 (es) 2000-05-11 2006-05-16 Bristol-Myers Squibb Company Analogos de tetrahidroisoquinolina utiles como secretores de la hormona del crecimiento.
AU2001264977B2 (en) 2000-05-30 2005-04-14 Merck & Co., Inc. Melanocortin receptor agonists
TR200401029T4 (tr) 2000-06-09 2004-06-21 Aventis Pharma Deutschland Gmbh Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
KR100833089B1 (ko) 2000-12-21 2008-05-29 사노피-아벤티스 도이칠란트 게엠베하 신규한 1,2-디페닐아제티딘온 및 당해 화합물을 함유하는 지질 대사 장애를 치료하기 위한 약제학적 조성물
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
EP1275653A1 (fr) 2001-07-10 2003-01-15 Bayer CropScience S.A. Oxazolopyridines et leur utilisation comme fungicides
PT1425014E (pt) 2001-08-31 2007-03-30 Sanofi Aventis Deutschland Derivados diarilcicloalquilo, processo para a sua preparação como activadores de ppar
EP1458374A2 (fr) * 2001-12-14 2004-09-22 Novo Nordisk A/S Composes ralentissant l'activite de la lipase hormono-sensible
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10215907A1 (de) 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10247680B4 (de) 2002-10-12 2005-09-01 Aventis Pharma Deutschland Gmbh Neue bicyclische Inhibitoren der Hormon Sensitiven Lipase
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258008B4 (de) 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
EP1615900A1 (fr) 2003-04-01 2006-01-18 Eli Lilly And Company Amides de l'acide benzisothiazol-3-one-carboxylique inhibiteurs des phospholipase
EP1613608A1 (fr) 2003-04-01 2006-01-11 Eli Lilly And Company Inhibiteurs de la phospholipase
RU2229478C1 (ru) * 2003-05-20 2004-05-27 ООО "Исследовательский институт химического разнообразия" Замещенные [1.3]оксазоло[4,5-d]пиридазины и комбинаторная библиотека
DE102004005172A1 (de) 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel

Also Published As

Publication number Publication date
MX2007015347A (es) 2008-02-15
TW200716653A (en) 2007-05-01
UY29593A1 (es) 2007-01-31
HRP20100409T1 (hr) 2010-09-30
IL187730A0 (en) 2008-08-07
NO20080133L (no) 2008-03-05
MY142792A (en) 2010-12-31
US20110039883A1 (en) 2011-02-17
EP1896485B1 (fr) 2010-05-19
EP1896485A1 (fr) 2008-03-12
DE502006006986D1 (de) 2010-07-01
AR054132A1 (es) 2007-06-06
RS51268B (sr) 2010-12-31
US20080167339A1 (en) 2008-07-10
BRPI0611688A2 (pt) 2010-09-28
SI1896485T1 (sl) 2010-09-30
PT1896485E (pt) 2010-08-05
CY1110213T1 (el) 2012-05-23
RU2007145499A (ru) 2009-06-20
WO2006131231A1 (fr) 2006-12-14
ES2346561T3 (es) 2010-10-18
CA2610325A1 (fr) 2006-12-14
KR20080019215A (ko) 2008-03-03
CN101193896A (zh) 2008-06-04
DK1896485T3 (da) 2010-09-06
JP2008542410A (ja) 2008-11-27
ATE468342T1 (de) 2010-06-15
NZ564063A (en) 2010-07-30
DE102005026762A1 (de) 2006-12-21
US7846943B2 (en) 2010-12-07
AU2006257022A1 (en) 2006-12-14
RU2414473C2 (ru) 2011-03-20
PL1896485T3 (pl) 2010-10-29
ZA200709501B (en) 2008-10-29

Similar Documents

Publication Publication Date Title
MA29481B1 (fr) Derives d'azolopyridine-2-one en tant qu'inhibiteurs de lipase et de phospholipase
MA29856B1 (fr) Derives de diacylindazole en tant qu'inhibiteurs de lipases et de phospholipases
MA29857B1 (fr) Derives de triazolopyridine en tant qu'inhibiteurs de lipases et phospholipases
EP2058317A4 (fr) Dérivé d'ester de l'acide aminophosphorique et modulateur de récepteur s1p contenant le dit dérivé en tant que principe actif
ECSP20027480A (es) Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
MA29858B1 (fr) Derives de carbamoylbenzotriazole en tant qu'inhibiteurs de lipases et phospholipases
ECSP088461A (es) Composiciones farmacéuticas que contienen buprenorfina
UY27362A1 (es) Métodos de usar inhibidores de epóxido hidrolasa soluble
FR17C1007I2 (fr) Quinazolinones utilisees en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase delta humaine
NI201100007A (es) Compuestos químicos 251.
MA31296B1 (fr) Derives d'imidazolidine carboxamide en tant qu'inhibiteurs de lipase et de phospholipase
UY29919A1 (es) Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones
HN2006019068A (es) "sintesis de (r)-n-metilnaltrexona"
MA28748B1 (fr) Applications galeniques de melanges auto-emulsionnants d'excipients lipidiques
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
EP1539122A4 (fr) Compositions pharmaceutiques de 2,6-diisopropylphenol aqueux
EP1819227A4 (fr) Formulation pharmaceutique de decitabine
EA200301019A1 (ru) Доставляемая перорально фармацевтическая композиция, включающая препарат с низкой растворимостью в воде (ингибитор cox-2), растворитель, жирную кислоту и органический амин
MA31567B1 (fr) Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique
PA8586801A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
MA31295B1 (fr) 5-oxo-isoxazoles en tant qu'inhibiteurs de lipases et de phospholipases
MA29482B1 (fr) Derives de benzothiazol-2-one derivatives en tant qu'inhibiteurs de lipase et de phospholipase
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
Pourjafar et al. All-trans retinoic acid enhances in vitro mesenchymal stem cells migration by targeting matrix metalloproteinases 2 and 9
BRPI0406824A (pt) Indolonaoxazoldinonas antiibacterianas, intermediários para seu preparo e composições farmacêuticas que as contêm